A new method for producing aminocyclopropanes has been developed, allowing for the creation of complex molecules under mild conditions. This breakthrough enables the exploration of new molecular structures with improved biological properties.
Researchers developed AI-powered 'tissue clocks' that estimate biological age from histological images, revealing organs age at different rates throughout life. The study identifies strong links between tissue-specific aging and medical conditions or lifestyle-associated factors.
Researchers identified NUDT5 as a key player in the molecular mechanisms determining whether cells succumb to or survive 6-TG. Targeted protein degradation revealed that degrading NUDT5 protects cells from the drug's toxic effects.
A new study mapped nearly 10,000 environmental exposures to human genes, revealing clusters of chemicals that disrupt common biological functions. The researchers found that exposures targeting central proteins tend to be more damaging, and that the 'distance' between an exposure and a disease can predict health outcomes.
Researchers will develop genetic boosters and "two-factor authentication" for CAR T cell therapy, targeting HER2-positive lung, breast, and colon tumors. The project aims to improve the efficacy of CAR T cells against solid tumors while reducing collateral damage.
Researchers discovered a small molecule that degrades SMARCA2/4 by engaging two distinct E3 ligase systems, creating a molecular backup for targeted protein degradation. This dual-engagement effectively increases the robustness of cancer therapies by making it harder for cells to escape treatment.
The tumor microbiota is now considered a crucial component of the tumor microenvironment, influencing cancer development and modulating immunotherapy effectiveness. Researchers have identified ways microbes can remodel tumors' microenvironments, directly interacting with tumor tissue and immune cells.
LazySlide enables systematic whole-slide image analysis using AI models and links visual patterns to text concepts. The study demonstrates its potential in analyzing tissue samples, identifying biological pathways, and reducing the barrier for applying advanced image analysis methods.
Researchers developed a new method to discover molecular glues through large-scale chemistry and cell-based screening. They identified compounds that selectively degrade ENL in leukemia cells, demonstrating the potential of this approach for targeting previously undruggable proteins.
Researchers have identified a new class of small molecules that boost the cell's natural recycling machinery to destroy an immune-modulating enzyme called IDO1. This approach takes a bolder approach than traditional drug design, eliminating disease-causing proteins altogether and opening up new possibilities for cancer treatment.
A new study reveals that kinase inhibitors can accelerate the degradation of targeted proteins, which is not a rare quirk but a common mechanism. This discovery could help design better drugs that remove kinases altogether or explain unexpected effects of existing therapies.
Researchers developed CellWhisperer, an AI method and software tool that links gene expression with descriptive text across millions of biological samples. It provides a virtual AI-based colleague to support biologists in their research, making biomedical data exploration easier and more exciting.
Researchers identified NUDT5 as a structural regulator that controls purine synthesis by physically restraining the key biosynthetic step. This mechanism may also explain cancer drug resistance and informs new therapeutic approaches for diseases caused by MTHFD1 deficiency.
Researchers identified key genes connected to cellular lipid metabolism that guide the precise release of cytotoxic granules in human NK and T cells. This discovery explains how immune cells work and sheds light on diseases caused by genetic defects.
Scientists have developed a new method to systematically discover genetic boosters for CAR T cells, a type of immune therapy. By knocking out genes that weaken CAR T cell function, researchers found a surprising genetic target: RHOG, which increases therapeutic potential when knocked out with CRISPR technology.
A team of researchers identified a complex network of regulatory proteins responsible for triggering the most appropriate immune response in macrophages. This study offers new insights into macrophage biology and sheds light on how these cells coordinate their responses to various pathogens.
Scientists have comprehensively studied the function and structure of SLC13A5 membrane transporter, revealing molecular mechanisms linked to severe epilepsy. The study analyzed nearly ten thousand genetic mutations and identified disease-causing variants, shedding new light on the mechanisms of this disease.
A decade-long project has provided the first comprehensive functional blueprint of chemical transport pathways in human cells. The RESOLUTE consortium's groundbreaking studies have more than doubled existing knowledge on solute carriers, offering powerful new resources for biomedical discovery.
Researchers developed a precision medicine approach that uses high-tech microscopy to analyze individual immune cells and identify cellular phenotypes correlated with disease activity and therapeutic response. This study represents a major step forward in tailoring therapies for rheumatoid arthritis and other autoimmune diseases.
Researchers have developed a new geometric machine learning method called MaSIF, which enables the design of proteins that bind specifically to desired molecular structures. This approach accelerates precision drug development by allowing for precise dosing and control of biological drugs.
Georg Winter's ERC Consolidator Grant has significantly advanced small molecule strategies for degrading cancer proteins, publishing over 30 studies in leading journals. His work on altering gene regulation holds tremendous potential for rewriting the genetic program of cancer cells and developing targeted therapies.
Scientists have identified a molecular mechanism that eliminates defective cells during faulty cell division, shedding new light on the fundamental processes involved. The discovery could lead to more effective treatments for blood cancer by targeting cells with multiple centrosomes, which are a hallmark of disrupted division.
A new adapter molecule recruits a previously unknown E3 ligase for targeted protein degradation, expanding therapeutic options for cancer and rare diseases. The discovery offers advantages in development due to the molecule's smaller size and potential for tissue-specific application.
Researchers at CeMM have identified a synthetic variant inspired by the Withanolides group that acts highly specifically against leukemia cells. The molecule disrupts the cholesterol metabolism of tumor cells.
Researchers at CeMM and Pfizer have developed a novel method to measure the binding activity of hundreds of small molecules against thousands of human proteins. The study revealed tens of thousands of ligand-protein interactions that can now be explored for drug development.
A team of researchers found that immune cells maintain their alertness through the JAK-STAT signalling pathway when there is no immediate threat. This discovery could lead to new approaches for enhancing the immune system's attention and preventing autoimmune diseases.
Researchers at CeMM Research Center create 'vpCells' method for simultaneous fluorescent labelling of many proteins, enabling precise tracking and exploration of protein function. The approach opens up new applications in fundamental cell biology and drug discovery.
Research reveals a dynamic pattern of gene expression in liver fibrosis, with persistent effects even during regression. The study identifies key 'hub' genes that could be developed into biomarkers for future therapies.
Scientists at CeMM Research Center have discovered a new method to mark proteins for destruction, potentially treating diseases like cancer. The technique uses 'intramolecular bivalent glues' to alter the protein's surface, triggering targeted protein degradation via ubiquitin ligases.
Researchers have found that the BCG vaccine can enhance innate immunity in individuals with dormant immune cells, predicting a positive response to vaccination. Trained immunity responders exhibited increased production of inflammatory mediators after vaccination.
Scientists have discovered a new small molecule called Feeblin that inhibits the interaction of SLC15A4 with TASL, a key player in pro-inflammatory signalling pathways. This finding offers promising new treatment options for patients with autoimmune diseases like systemic lupus.
Clarissa Campbell and Barbara Maier receive prestigious ERC Starting Grants for their research on the interplay between the immune system and metabolism, as well as the role of lymph nodes in cancer. The grants will support their work on understanding immune cells in the gut and the crosstalk between tumors and lymph nodes.
Scientists at CeMM and Max Perutz Labs have reclassified approximately 200 rare immune system disorders using a network-based approach. The study reveals strong similarities between rare diseases and autoimmune conditions, enabling the prediction of treatment efficacy and personalized approaches for diagnosis and treatment.
Scientists have developed a new assay system to target lactate transporters SLC16A1 and SLC16A3, associated with certain cancers and diseases. The method enables the discovery of highly selective inhibitors, providing a potential new approach for cancer treatments.
Scientists have mapped and analyzed DNA methylation profiles in 580 different animal species, providing insights into the evolutionary conservation of epigenetic mechanisms. The study reveals that DNA methylation constitutes a cancer-protective mechanism in large animals with long lifespans, contradicting Peto's paradox.
In a recent study, researchers targeted the POL theta enzyme to inhibit DNA production in cancer cells. The approach represents a new method for developing specific therapies for patients with BRCA1 mutations.
A study by CeMM researchers and the University of Dundee identifies mutations in E3 ligases that mediate resistances in cell cultures, but also finds that these mutations can be targeted by chemically modified degraders. This understanding has clinical relevance and enables further improvement of cancer therapy drugs.
Researchers developed a non-invasive algorithm to identify patients with compensated cirrhosis at highest risk for severe complications. The online calculator uses widely available laboratory parameters and is simple, non-invasive, and cost-effective.
Researchers at CeMM have discovered that targeting SMNDC1 in alpha cells can induce insulin production, a potential new approach for treating diabetes. The study identified a key molecular mechanism regulating insulin hormone production and its essential role in the treatment of diabetes.
Researchers have identified a novel gene FIBCD1 as likely causative of rare neurodevelopmental disorders. The study found that FIBCD1 is a receptor for ECM 'sugar' components and linked to diseases such as autism, ADHD, schizophrenia, and Alzheimer's.
Researchers developed a new method for generating network layouts that allow for visualizing different information in two- and three-dimensional virtual space. This facilitates the exploration of complex protein interactions and provides more versatile, comprehensible representations of networks.
Researchers at CeMM Research Center discovered that the DNA mismatch repair process plays a crucial role in prime editing. By eliminating mismatch repair, they increased prime editing efficiency by 2-17-fold and improved its accuracy. This fundamental understanding brings the technology closer to clinical applications.
Researchers identified specific metabolic vulnerabilities in leukemia cell lines, including sensitivity to PI3K and fatty acid synthase inhibitors. The study highlights the potential for targeted cancer therapy by exploiting these dependencies.
A new multiplex network developed by Jörg Menche's research group maps all genes and their interactions, improving the identification of genetic defects and assessing their consequences. The network increases the probability of finding the crucial gene aberration threefold compared to separate networks.
Researchers discovered that skin-derived T cells can migrate into the bloodstream and cause inflammation in other organs, such as the intestine. The study provides new approaches to therapy and diagnostic options for stem cell transplantation.
Researchers conducted a functional test to identify effective therapies for advanced hematological cancers, achieving significant positive outcomes with 56 patients receiving individually tailored treatment. The study demonstrates the clinical feasibility and efficacy of personalized medicine in breaking resistance to prior therapies.
Cachexia is characterized by weight loss and muscle tissue shrinkage, driven by the immune system's response to chronic infections and diseases. Researchers from CeMM emphasize the need for more research into cachexia, highlighting the importance of interplay between the immune system and metabolism.
Researchers at CeMM have developed an eco-friendly process to synthesize organic materials using water instead of toxic solvents, achieving cost savings of up to 25% and improving material properties. The process involves heating molecules in water under pressure to create high-performance materials with unique structures and properties.
Researchers from CeMM Research Center have developed a new method called scifi-RNA-seq that enables efficient RNA sequencing for millions of individual cells. This method marks the RNA of many cells with specific barcodes, allowing for analysis of complex tissues and organs.
Researchers found that purines can trigger a functional disturbance of BRD4 and impact chromatin accessibility. Adenine restores BRD4 functionality, suggesting its potential as a new therapeutic approach for BRD4-induced cancer types.